NASDAQ:PAHCPhibro Animal Health Stock Price, Forecast & News

$25.44

-0.76 (-2.90 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$25.40

Now: $25.44▼

$26.29

50-Day Range

$22.31

MA: $24.14▼

$28.29

52-Week Range

$16.87

Now: $25.44▼

$33.97

Volume165,875 shs

Average Volume180,176 shs

Market Capitalization$1.03 billion

P/E Ratio28.27

Dividend Yield1.83%

Beta0.45

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Phibro Animal Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $24.80, Phibro Animal Health has a potential downside of 2.5% from its current price of $25.44.
Amount of Analyst Coverage
Phibro Animal Health has only been the subject of 2 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Phibro Animal Health has received 289 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Phibro Animal Health has received 355 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Phibro Animal Health has received 55.12% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote “Outperform” if you believe PAHC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Phibro Animal Health is a leading dividend payer. It pays a dividend yield of 1.83%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Phibro Animal Health has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of Phibro Animal Health is 31.37 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Phibro Animal Health will have a dividend payout ratio of 40.00 % next year. This indicates that Phibro Animal Health will be able to sustain or increase its dividend.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phibro Animal Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
50.05% of the stock of Phibro Animal Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.66% of the stock of Phibro Animal Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Phibro Animal Health are expected to grow by 11.11% in the coming year, from $1.08 to $1.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phibro Animal Health is 28.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.51.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phibro Animal Health is 28.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.41.
Price to Earnings Growth Ratio
Phibro Animal Health has a PEG Ratio of 17.33. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Phibro Animal Health has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PAHC

Previous Symbol

CUSIPN/A

CIK1069899

Webwww.pahc.com

Phone201-329-7300

Debt

Debt-to-Equity Ratio1.79

Current Ratio2.72

Quick Ratio1.62

Price-To-Earnings

Trailing P/E Ratio28.27

Forward P/E Ratio23.56

P/E Growth17.33

Sales & Book Value

Annual Sales$828 million

Price / Sales1.24

Cash Flow$2.17 per share

Price / Cash Flow11.72

Book Value$5.34 per share

Price / Book4.76

Profitability

EPS (Most Recent Fiscal Year)$1.53

Net Income$54.71 million

Net Margins4.48%

Return on Equity24.23%

Return on Assets6.56%

Miscellaneous

Employees1,600

Outstanding Shares40,453,000

Market Cap$1.03 billion

Next Earnings Date8/25/2020 (Estimated)

OptionableOptionable

Receive PAHC News and Ratings via Email

Sign-up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.

Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions

How has Phibro Animal Health's stock been impacted by COVID-19 (Coronavirus)?

Phibro Animal Health's stock was trading at $24.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PAHC stock has increased by 3.5% and is now trading at $25.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Phibro Animal Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Phibro Animal Health.

When is Phibro Animal Health's next earnings date?

Phibro Animal Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Phibro Animal Health.

How were Phibro Animal Health's earnings last quarter?

Phibro Animal Health Corp (NASDAQ:PAHC) announced its earnings results on Thursday, May, 7th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.04. The firm earned $210.70 million during the quarter. Phibro Animal Health had a net margin of 4.48% and a return on equity of 24.23%. View Phibro Animal Health's earnings history.

How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?

Phibro Animal Health declared a quarterly dividend on Monday, May 4th. Shareholders of record on Wednesday, June 3rd will be given a dividend of $0.12 per share on Wednesday, June 24th. This represents a $0.48 annualized dividend and a yield of 1.89%. The ex-dividend date of this dividend is Tuesday, June 2nd. View Phibro Animal Health's dividend history.

What price target have analysts set for PAHC?

5 brokerages have issued 12-month price targets for Phibro Animal Health's stock. Their forecasts range from $18.00 to $30.00. On average, they expect Phibro Animal Health's stock price to reach $24.80 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View analysts' price targets for Phibro Animal Health.

Has Phibro Animal Health been receiving favorable news coverage?

Media headlines about PAHC stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Phibro Animal Health earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutPhibro Animal Health.

Are investors shorting Phibro Animal Health?

Phibro Animal Health saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 771,200 shares, an increase of 7.4% from the April 15th total of 718,100 shares. Based on an average daily volume of 192,900 shares, the days-to-cover ratio is presently 4.0 days. Currently, 3.8% of the shares of the stock are short sold. View Phibro Animal Health's Current Options Chain.

Who are some of Phibro Animal Health's key competitors?

Some companies that are related to Phibro Animal Health include Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), Allakos (ALLK), PTC Therapeutics (PTCT) and Arena Pharmaceuticals (ARNA). View all competitors.

What other stocks do shareholders of Phibro Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zoetis (ZTS), Zynerba Pharmaceuticals (ZYNE), Banco Bradesco (BBD), Booking (BKNG) and Epirus Biopharmaceuticals (EPRSQ).

Who are Phibro Animal Health's key executives?

Phibro Animal Health's management team includes the following people:

Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 72)
Mr. Larry L. Miller, Chief Operating Officer (Age 55)
Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 50)
Mr. Richard G. Johnson, Chief Financial Officer (Age 70)
Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 61)

What is Phibro Animal Health's stock symbol?

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Who are Phibro Animal Health's major shareholders?

Phibro Animal Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.19%), Principal Financial Group Inc. (4.86%), State Street Corp (1.80%), Janus Henderson Group PLC (1.68%), Fiduciary Management Inc. WI (1.57%) and Nuveen Asset Management LLC (1.28%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran and Jack Bendheim. View institutional ownership trends for Phibro Animal Health.

Which institutional investors are selling Phibro Animal Health stock?

PAHC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Janus Henderson Group PLC, BlackRock Inc., Wells Fargo & Company MN, Eagle Asset Management Inc., Mackay Shields LLC, Squarepoint Ops LLC, and Fiduciary Management Inc. WI. View insider buying and selling activity for Phibro Animal Health.

Which institutional investors are buying Phibro Animal Health stock?

PAHC stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Copper Rock Capital Partners LLC, Raymond James & Associates, Nuveen Asset Management LLC, Parametric Portfolio Associates LLC, Ziegler Capital Management LLC, State Street Corp, and 361 Capital LLC. View insider buying and selling activity for Phibro Animal Health.

How do I buy shares of Phibro Animal Health?

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phibro Animal Health's stock price today?

One share of PAHC stock can currently be purchased for approximately $25.44.

How big of a company is Phibro Animal Health?

Phibro Animal Health has a market capitalization of $1.03 billion and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.

What is Phibro Animal Health's official website?

The official website for Phibro Animal Health is www.pahc.com.

How can I contact Phibro Animal Health?

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff